What is claimed is:

1. A compound of Formula (I)



(I)

or pharmaceutically acceptable salt or solvate thereof

wherein

A^1 and A^2 are each independently C_{1-4}alkylene or a bond;

A^3 is a bond, C_{1-4}alkylene or C_{1-4}alkylidene;

A^4 is C_{1-4}alkylene or a bond and is attached to X, X^1 or X^2;

X, X^1, X^2 and X^3 are independently C or CH;

J is C_{1-4}alkyl;

p is 0 or 1;

R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C_{1-4}alkyl or C_{1-4}alkyl-N(H)C(O)O-;

said C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy, indolyl or halo;

wherein said indolyl is optionally substituted by halo or cyano;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy, cyano or benzyl;

R^3 is H or C_{1-4}alkyl;

m is 0 or 1;

R^4 and R^5 are independently hydrogen, cyano, halo, nitro, C_{1-3}alkyl or C_{1-3}perfluoroalkyl;

wherein said R^4 or R^5 may be independently attached to G^1, X, X^1, X^2 or X^3;

n is 0 or 1;

G is N, O or S;

G^1 is N, C or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both R^4 and R^5 are not attached to the same of said G^1, X, X^1, X^2 or X^3;

if G is O or S, then m is 0;

if G is N, then m is 1;

if R_1 is C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R_2 is H or C_{1-3}alkyl;

if R_2 is C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R_1 is H or C_{1-3}alkyl;

if $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy, cyano or benzyl, then p is 0;

if R^1 is $-N(H)C(O)OC_{1-4}$alkyl, C_{1-4}alkyl-$N(H)C(O)O-$ or said heterocyclic moiety wherein said heterocyclic moiety

contains a nitrogen atom and said nitrogen atom is attached to A^1, then A^1 is C_{2-4}alkylene;

if R^2 is -N(H)C(O)OC_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2, then A^2 is C_{2-4}alkylene;

if R^1 is N(H)C(O)O-C_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano, then R^2 is H or C_{1-3}alkyl;

if R^2 is -N(H)C(O)O-C_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano, then R^1 is H or C_{1-3}alkyl;

if R^4 or R^5 are attached to G^1, then G^1 is C;

if A^4, R^4 or R^5 are attached to X, then X is C;

if A^4, R^4 or R^5 are attached to X^1, then X^1 is C;

if A^4, R^4 or R^5 are attached to X^2, then X^2 is C;

if R^4 or R^5 are attached to X^3, then X^3 is C.

2. A compound according to claim 1 wherein p is 0.
3. A compound according to claim 1 wherein G is N and G^1 is CH.
4. A compound according to claim 1 wherein G is S and G^1 is CH.
5. A compound according to claim 1 wherein G is N and G^1 is N.
6. A compound according to claim 1 wherein G is S and G^1 is N.
7. A compound according to claim 1 wherein G is O and G^1 is N.
8. A compound according to claim 1 wherein R^1 is methyl and R^2 is methyl.
9. A compound according to claim 1 wherein R^1 is H and R^2 is C_{3-6}cycloalkyl wherein said C_{3-6}cycloalkyl is substituted with indolyl and wherein said indolyl is optionally substituted by halo or cyano.
10. A compound according to claim 1 wherein A^1 is a bond, R^1 is methyl, A^2 is a bond and R^2 is methyl.
11. A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C_{1-4}alkyl or C_{1-4}alkyl-N(H)C(O)O-; said C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy or halo.
12. A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3}alkyl, phenyl, said phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy or halo.
13. A compound according to claim 1 wherein R^1 and R^2 are independently H or unsubstituted C_{1-3}alkyl or phenyl.
14. A compound according to claim 1 wherein R^1 and R^2 are independently H or unsubstituted C_{1-3}alkyl or phenyl and A^1 and A^2 are independently C_{1-4}alkylene.
15. A compound according to claim 1 wherein -A^1-R^1 and -A^2-R^2 together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl,

dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy, cyano or benzyl.

16. A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form unsubstituted pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl.
17. A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form unsubstituted pyrrolidinyl, piperidinyl, morpholino or isoindolinyl.
18. A compound according to claim 1 wherein R^3 is H and m is 1.
19. A compound according to claim 1 wherein n is 0.
20. A compound according to claim 1 wherein R^4 and R^5 are halo.
21. A compound according to claim 1 wherein R^4 is C_{1-3}alkyl and is attached to G^1.
22. A compound according to claim 1 wherein R^4 is C_{1-3}perfluoroalkyl and is attached to G^1.
23. A compound according to claim 1 wherein R^4 is hydrogen.
24. A compound according to claim 1 wherein R^4 is fluoro.
25. A compound according to claim 1 wherein R^4 is cyano.
26. A compound according to claim 1 wherein R^4 is cyano or fluoro.
27. A compound according to claim 1 wherein R^4 and R^5 are each fluoro.
28. A compound according to claim 1 wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.
29. A compound according to claim 1 wherein the hydrogen atom attached to D is in the *cis* configuration to the hydrogen atom attached to E.
30. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S.
31. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of R.

32. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of S.
33. A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of R.
34. A compound according to claim 1 wherein A^3 is a bond.
35. A compound according to claim 1 wherein A^3 is C_{1-4}alkylene.
36. A compound according to claim 1 wherein A^3 is C_{1-4}alkylidene.
37. A compound according to claim 1 wherein A^3 is methylene.
38. A compound according to claim 1 wherein A^4 is a bond.
39. A compound according to claim 1 wherein A^4 is methylene.
40. A compound according to claim 1 wherein A^4 is attached X^1.
41. A compound according to claim 1 wherein A^4 is attached X.
42. A compound according to claim 1 wherein R^4 is attached X.
43. A compound according to claim 1 wherein

A^1 and A^2 are each independently C_{1-4}alkylene or a bond;

A^3 is a bond;

A^4 is a bond and is attached to X^1;

X and X^1 are each C;

X^2 and X^3 are each CH;

p is 0;

R^1 and R^2 are independently H, C_{1-3}alkyl, C_{3-6}cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C_{1-4}alkyl or C_{1-4}alkyl-N(H)C(O)O-;

said C_{3-6}cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4}alkyl, C_{1-3}alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy, cyano or benzyl;

R^3 is H;

m is 1;

R^4 is hydrogen, cyano, halo, nitro, C_{1-3}alkyl or C_{1-3}perfluoroalkyl and is attached to X;

n is 0;

G is N;

G^1 is CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if R^1 is -N(H)C(O)OC_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1, then A^1 is C_{2-4}alkylene;

if R^2 is -N(H)C(O)OC_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2, then A^2 is C_{2-4}alkylene;

if R^1 is N(H)C(O)O-C_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano, then R^2 is H or C_{1-3}alkyl; and

if R^2 is -N(H)C(O)O-C_{1-4}alkyl, C_{1-4}alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C_{1-4}alkyl, C_{1-4}alkoxy or cyano, then R^1 is H or C_{1-3}alkyl.

44. A pharmaceutically acceptable formulation comprising a compound according to claim 1.

45. A method of treating depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders and sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

46. A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

47. A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

48. A compound or pharmaceutically acceptable salt or solvate thereof selected from the group consisting of

3-(3-methylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-ethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dimethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(ethyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-diethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(1,3-dihydro-isoindol-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-[3-(3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-penethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-morpholin-4-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-benzylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-piperidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dipropylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-propylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;

1-methyl-3-(3-methylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-ethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-(3-benzylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-phenethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dimethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-[3-(ethyl-methyl-amino)-cyclopentyl]-1-methyl-1*H*-indole-5-carbonitrile;
3-(3-diethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-piperidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-morpholin-4-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-propylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dipropylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-ethyl-1*H*-indole-5-carbonitrile;
3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
3-(5-fluoro-1*H*-indol-3-yl)-cyclopenty]-dimethyl-amine;
ethyl-[3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl]-methyl-amine;
diethyl-[3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl]-amine;
5-fluoro-3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole;
3-(4-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(4-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-dhloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-iodo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-fluoro-1H-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-chloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-chloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
(*1S,3R*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;
(*1S,3S*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;

(*1R,3S*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;

(*1R,3R*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;

(*1S,3S*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;

(*1R,3S*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;

(*1R,3R*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;

(*1S,3R*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;

(*1S,3R*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;

(*1S,3S*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;

(*1R,3S*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;

(*1R,3R*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;

(*1S*)-3-(3-amino-cyclopentyl)-1*H*-indole-5-carbonitrile; and

(*3S,3'S*)-bis-(3-(5-cyano-1*H*-indol-3-yl)cyclopentyl)amine.